Table I.
Clinicopathological characteristics of patients according to the ALK fusion and EGFR mutation status.
| ALK FISH-positive (n=39) | ALK FISH-negative and EGFR mutation-negative (n=329) | ALK FISH-negative and EGFR mutation-positive (n=114) | ALK IHC-positive (n=74) | |
|---|---|---|---|---|
| Sex | ||||
| Male | 23 (59.0%) | 198 (60.2%) | 70 (61.4%) | 38 (51.4%) |
| Female | 16 (41.0%) | 131 (39.8%) | 44 (38.6%) | 36 (48.6%) |
| Smoking history | ||||
| Never | 21 (53.8%) | 141 (42.9%) | 72 (63.2%) | 39 (52.7%) |
| Previous or current | 18 (46.2%) | 188 (57.1%) | 42 (36.8%) | 35 (47.3%) |
| Mean age | 60.7 years | 66.5 years | 64.3 years | 63.7 years |
| Nodal metastasis | 31 (79.5%) | 223 (67.8%) | 72 (63.2%) | 58 (78.4%) |
| Tumor stage | ||||
| I | 6 (15.4%) | 83 (25.2%) | 37 (32.5%) | 7 (9.5%) |
| II | 3 (7.7%) | 30 (9.1%) | 15 (13.2%) | 10 (13.5%) |
| III | 9 (23.1%) | 59 (17.9%) | 21 (18.4%) | 25 (33.8%) |
| IV | 21 (53.8%) | 157 (47.7%) | 41 (36.0%) | 32 (43.2%) |
| 1-year mortality | 16 (41.0%) | 31 (41.9%) | ||
ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridization.